Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay
(firmenpresse) - HERCULES, CA -- (Marketwired) -- 11/18/14 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products life science research and clinical diagnostic products, today announced that it has received Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's Geenius™ HIV 1/2 Supplemental Assay (test).
The Geenius HIV 1/2 Supplemental Assay is a single-use immunochromatographic assay intended for use as an additional, more specific, test to confirm the presence of and differentiate antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1 and HIV-2) for specimens found to be repeatedly reactive by diagnostic screening procedures. The assay may also be used to confirm the presence of antibodies to HIV-1 and/or HIV-2 in pediatric subjects (children as young as 2 years old).
"Bio-Rad is pleased to offer its Geenius HIV 1/2 Supplemental Assay," said John Hertia, Bio-Rad Executive Vice President, President, Clinical Diagnostics Group. "Using the assay, clinicians are able to help HIV-infected individuals get the correct treatment they need more quickly. Bio-Rad has a long history of providing laboratories the tools that they need for HIV detection."
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, please visit our website at .
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communicatons
510-741-6063
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2014 - 21:15 Uhr
Sprache: Deutsch
News-ID 353717
Anzahl Zeichen: 0
contact information:
Town:
HERCULES, CA
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay"
steht unter der journalistisch-redaktionellen Verantwortung von
Bio-Rad Laboratories (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
